Mark Wingertzahn - Kaleido Biosciences VP Devel
| KLDODelisted Stock | USD 0.01 0.00 0.00% |
Insider
Mark Wingertzahn is VP Devel of Kaleido Biosciences
| Age | 51 |
| Phone | 617 674 9000 |
| Web | https://kaleido.com |
Kaleido Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.9993) % which means that it has lost $0.9993 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.8057) %, meaning that it created substantial loss on money invested by shareholders. Kaleido Biosciences' management efficiency ratios could be used to measure how well Kaleido Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Kaleido Biosciences currently holds 5.55 M in liabilities with Debt to Equity (D/E) ratio of 2.05, implying the company greatly relies on financing operations through barrowing. Kaleido Biosciences has a current ratio of 1.39, which is within standard range for the sector. Debt can assist Kaleido Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Kaleido Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Kaleido Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Kaleido to invest in growth at high rates of return. When we think about Kaleido Biosciences' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Adam Zlotnick | Assembly Biosciences | N/A | |
| RAC Sakai | Tempest Therapeutics | N/A | |
| Michelle Doig | Nuvation Bio | 46 | |
| Robert Bazemore | Nuvation Bio | 53 | |
| Justin Trojanowski | Tempest Therapeutics | 36 | |
| MPH MD | NRx Pharmaceuticals | 68 | |
| Kathryn Falberg | Nuvation Bio | 60 | |
| Prof Javitt | NRx Pharmaceuticals | N/A | |
| Robert MIM | NRx Pharmaceuticals | 58 | |
| Surendra Singh | Inhibikase Therapeutics | N/A | |
| Sandeep MD | Instil Bio | 56 | |
| Tharaknath Rao | Assembly Biosciences | N/A | |
| MHROD SHRMSCP | Assembly Biosciences | N/A | |
| Daniel Welch | Nuvation Bio | 63 | |
| W Vernon | Nuvation Bio | 65 | |
| Bronson Crouch | Instil Bio | 52 | |
| Sumita JD | Instil Bio | 50 | |
| Petpiboon Prasit | Tempest Therapeutics | N/A | |
| Jamie Moore | CytomX Therapeutics | N/A | |
| Roger Rush | Inhibikase Therapeutics | N/A | |
| BSc FRCPC | Inhibikase Therapeutics | N/A | |
Management Performance
| Return On Equity | -5.81 | ||||
| Return On Asset | -1.0 |
Kaleido Biosciences Management Team
Elected by the shareholders, the Kaleido Biosciences' board of directors comprises two types of representatives: Kaleido Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kaleido. The board's role is to monitor Kaleido Biosciences' management team and ensure that shareholders' interests are well served. Kaleido Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kaleido Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Wingertzahn, VP Devel | ||
| Kimberly Hocknell, VP Operations | ||
| LLM JD, Chief Advisor |
Kaleido Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Kaleido Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -5.81 | ||||
| Return On Asset | -1.0 | ||||
| Operating Margin | (79.28) % | ||||
| Current Valuation | (16.73 M) | ||||
| Shares Outstanding | 42.62 M | ||||
| Shares Owned By Insiders | 0.73 % | ||||
| Shares Owned By Institutions | 0.36 % | ||||
| Number Of Shares Shorted | 2.34 M | ||||
| Price To Earning | (1.45) X | ||||
| Price To Book | 0 X |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Other Consideration for investing in Kaleido Pink Sheet
If you are still planning to invest in Kaleido Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kaleido Biosciences' history and understand the potential risks before investing.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |